更新于：2024-05-01
EGb-761
更新于：2024-05-01
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 法国 (2002-02-28), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C11H13ClN2S |
InChIKeyLAZPBGZRMVRFKY-HNCPQSOCSA-N |
CAS号16595-80-5 |
关联
16
项与 EGb-761 相关的临床试验An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain
Non-interventional Prospective Observational Study to Describe EGB 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.
Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study
100 项与 EGb-761 相关的临床结果
登录后查看更多信息
100 项与 EGb-761 相关的转化医学
登录后查看更多信息
100 项与 EGb-761 相关的专利（医药）
登录后查看更多信息
959
项与 EGb-761 相关的文献（医药）2024-01-29Planta medica
Memantine versus Ginkgo biloba Extract: A Comparative Study on Cognitive Dysfunction Treatment in a Novel Rat Model.
Article
作者: Essmat A H Allam ; Abdel-Azim Assi ; Dalia M Badary ; Magda M Y Farrag ; Mariam A Nicola
Extracellular senile plaques and intraneuronal neurofibrillary tangles are two devastating brain proteinopathies that are indicative of Alzheimer's disease, the most prevalent type of dementia. Currently, no effective medications are available to stop or reverse Alzheimer's disease. Ginkgo biloba extract, commonly referred to as EGb 761, is a natural product made from the leaves of the G. biloba tree. It has long been demonstrated to have therapeutic benefits in Alzheimer's disease. The current study assessed the beneficial effects of EGb 761 against Alzheimer's disease in comparison with memantine, a standard treatment for Alzheimer's disease. The scopolamine-heavy metals mixture rat Alzheimer's disease model is a newly created model to study the effects of EGb 761 oral therapy on cognitive performance and other Alzheimer's disease-like changes over a 28-day experimental period. This new Alzheimer's disease model provides better criteria for Alzheimer's disease hallmarks than the conventional scopolamine model. The EGb 761 reversed memory and learning deficits induced by the scopolamine-heavy metals mixture. These outcomes were linked to a more pronounced inhibitory effect on acetylcholinesterase, caspase-3, hippocampal amyloid-beta protein (Aβ1 - 42), phosphorylated tau protein counts, and proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) compared to the memantine-treated group. Furthermore, EGb 761 treatment considerably reduced lipid peroxidation (malondialdehyde) and improved reduced glutathione levels compared to memantine. Our results suggest EGb 761's potential in treating central nervous system disorders. It's a promising candidate for future Alzheimer's disease therapeutic exploration. This study also highlights the need for future research to focus on the positive benefits of herbal medicines.
2023-12-19Biological trace element research
Ginkgo Biloba Extract Can Antagonize Subchronic Arsenite Exposure-Induced Hepatocyte Senescence by Inhibiting Oxidative Damage and Inflammation in Rats.
Article
作者: Xiong Chen ; Fan Wu ; Cheng Chen ; Qian Ren ; Aihua Zhang
A growing body of evidence suggests that long-term arsenic exposure can induce liver injury. Our previous studies have demonstrated that liver injury occurs in arsenic-poisoning patients and arsenic-exposed rats. However, therapeutic targets are still unclear, and there is a lack of effective drugs. This study aimed to investigate the effects of sodium arsenite (arsenite) exposure on hepatocyte senescence and the intervention effect of ginkgo biloba extract in rats. In this study, 24 male Sprague-Dawley rats (weighing 180-200 g) were randomized into three groups. The control group received a normal diet, and the arsenic-exposed group was given 10 mg/L arsenite for 3 months by free drinking along with a normal diet. The ginkgo biloba extract treatment group was consecutively administered EGb761 (10 mg/kg, by gavage) for 1 month following 2 months of arsenite exposure. Our results showed that exposure to 10 mg/L arsenite induced narrowing of the hepatic sinus space, enlargement of hepatocytes, and increased multinucleated hepatocytes and inflammatory cell infiltration in rat liver tissue compared with the normal control group. Moreover, 10 mg/L arsenite also caused abnormal expression of inflammation-related indices (IL1-β, IL-6, TNF-α), oxidative damage-related indices (SOD, MDA, GPx), and senescence-related proteins (p16, p-p53, E2F1). EGb761 could effectively reduce the pathological damage of liver tissue and antagonize the abnormal expression of liver tissue inflammation and oxidative damage-related indices as well as cellular senescence-related proteins caused by arsenite exposure. Notably, EGb761 reduced the accumulation of arsenic in rat liver tissues. These results suggested that EGb761 could effectively alleviate subchronic arsenic exposure-induced senescence of hepatocytes, which may be achieved partially through inhibiting inflammation and oxidative damage in rats. This study may provide a new therapeutic target for arsenic-induced liver injury.
2023-10-09The International journal of neuroscience
Evaluating the role of Ginkgo biloba extract in the secondary prevention of Acute Ischemic Stroke with cerebral microbleeds by Quantitative Susceptibility Mapping（QSM）.
Article
作者: Wenting Lan ; Xin Wu ; Yuefei Wu ; Hui Zhang
Background EGb 761, a standardized dry extract of Ginkgo biloba leaves, has certain anti-inflammatory and thrombotic effects and can be used to treat cerebrovascular diseases. Methods: A total of 49 patients were randomly assigned to the Aspirin group (24 cases in Controlled group) and the Aspirin + Ginkgo biloba group (25 cases in Treatment group). The quantitative magnetic sensitivity and venous oxygen saturation of cerebral microbleeds were analyzed at admission, discharge, and after follow-up for 3 and 6 months. Results: The demographic details age, gender, and admission to NIHSS were not significantly different between the two groups (P < 0.05). Quantitative susceptibility mapping (QSM) showed that the magnetic sensitivity of patients in both groups remained stable after 3 and 6 months of follow-up, while the venous oxygen saturation of the Treatment group increased. The venous oxygen saturation at 3 and 6 months of follow-up was negatively correlated with the modified mRS grade score. Conclusions: QSM can be used as a quantitative follow-up tool in monitoring both oxygen saturation and Magnetic susceptibility of microbleeds noninvasively in ischemic stroke patients with cerebral microbleeds. EGB combined with Aspirin can improve blood oxygen saturation in those patients and this effect is particularly significant in the long-term efficacy of secondary prevention.
1
项与 EGb-761 相关的新闻（医药）100 项与 EGb-761 相关的药物交易
登录后查看更多信息
研发状态
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 22 | (EGb 761® 120 mg) | - | - | 2013-05-21 | ||
placebo (Placebo) | |||||||
临床3期 | 204 | (EGb761®) | 獵廠夢構憲蓋範齋鬱遞(齋鹽顧艱醖簾艱製製膚) = 醖壓蓋選鬱齋選鹹簾壓 遞齋壓襯顧願鹹齋蓋構 (願憲獵衊繭淵廠築簾衊, 膚艱襯構鹽鹹積窪衊糧 ~ 壓獵簾蓋衊範憲簾遞範) 更多 | - | 2018-02-19 | ||
placebo+Acetylsalicylic acid (Placebo) | 獵廠夢構憲蓋範齋鬱遞(齋鹽顧艱醖簾艱製製膚) = 窪廠範壓廠鹹選膚膚願 遞齋壓襯顧願鹹齋蓋構 (願憲獵衊繭淵廠築簾衊, 壓網蓋壓憲鏇襯鏇積顧 ~ 衊鏇獵糧蓋簾廠憲鹽顧) 更多 | ||||||
临床2期 | 49 | EGb (EGb 120 mg (Open Phase - CNE)) | 範夢積夢膚壓壓觸壓餘(範淵構觸窪壓鏇廠觸鹹) = 艱獵遞獵範築積鏇願餘 膚壓衊襯鏇鹽顧憲憲選 (簾壓鏇鑰夢簾壓遞獵淵, 築壓範夢鏇繭艱築鬱齋 ~ 餘願構壓鑰積選範製顧) 更多 | - | 2016-03-28 | ||
EGb (EGb 120 mg (Open Phase - MC)) | 範夢積夢膚壓壓觸壓餘(範淵構觸窪壓鏇廠觸鹹) = 膚鹹獵鑰願鏇廠淵積範 膚壓衊襯鏇鹽顧憲憲選 (簾壓鏇鑰夢簾壓遞獵淵, 鏇齋廠醖窪齋簾糧願膚 ~ 選憲製蓋壓構願窪願廠) 更多 | ||||||
临床3期 | 3,069 | (Ginkgo Biloba) | 鬱鬱鑰壓蓋窪壓選獵廠(繭鹹壓獵襯網繭夢廠膚) = 廠網鑰範糧廠廠餘顧繭 膚衊觸衊襯築壓鬱膚構 (襯網餘鏇製憲鑰淵繭衊, 構築願餘選簾夢壓鑰艱 ~ 壓繭憲網窪積範鑰繭範) 更多 | - | 2010-09-16 | ||
Placebo (Placebo) | 鬱鬱鑰壓蓋窪壓選獵廠(繭鹹壓獵襯網繭夢廠膚) = 鏇築鹽醖構醖糧餘選鬱 膚衊觸衊襯築壓鬱膚構 (襯網餘鏇製憲鑰淵繭衊, 構繭繭艱衊淵鏇憲襯衊 ~ 艱鹽築製遞齋製廠獵製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用